Funding for this research was provided by:
virios therapeutics, inc.
Article History
Received: 9 November 2021
Accepted: 31 March 2022
First Online: 21 April 2022
Declarations
:
: Financial interests: CD has received research support from and served as a paid consultant to Virios Therapeutics, Inc. WLP and RJW are shareholders in Virios Therapeutics, Inc.Non-financial interests: WLP and RJW are members of the Virios Therapeutics Board of Directors.
: This study was approved by the Institutional Review Boards of the University of Alabama and the Druid City Hospital Health System (FWA #00006291) in 2012 with annual renewals and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Informed consent was obtained from all study participants.